Lin Shi used the elimination method to exclude all the stocks that rose well and had little room for growth, and fixed his eyes on an ST stock - ST Tengguang.

Lin Shi found that this stock has been profitable for 7 consecutive years, but it still wears the hat of ST.

In fact, ST Tengguang has always been capped, one of which was because the promise of share reform was not completed. According to the announcement on May 14, Tengguang Group completed the procedure of divesting the equity of Tengguang Optoelectronics. In other words, ST Tengguang, who has made a profit for 7 consecutive years, may take off the hat of ST next year.

What does it mean to take off the hat of ST shares?

It means skyrocketing!

Just think about Shui Lanfang, before taking off the hat, it was a junk stock that no one cared about, and after taking off the hat, it suddenly became a dazzling new star in the liquor sector, and the stock price rose for 6 consecutive months, with a cumulative yield of 134%.

Of course.

This is an individual case, generally speaking, ST shares can have a conservative yield of 15%, if you are not greedy, grab a ST stock that takes off the hat, then this year's yield does not have to worry.

Lin Shi took a closer look at ST Tengguang's main business and found that it was a blood product, a high-growth and high-barrier industry.

Investors familiar with blood products know that the business outlook and profitability of blood products are attractive.

ST Tengguang is mainly engaged in the research and development, production and sales of blood products.

At present, there is an imbalance between supply and demand in the domestic market, so the blood products industry has high prosperity and high growth. The blood products industry has seen an unprecedented growth in 2016, and some blood products are still in a tight supply and demand situation. The industry expects that the market size of blood products is expected to reach 60 billion yuan in 2019. According to ST Tengguang's 2016 annual report, its blood product revenue accounted for 97.52% of the total revenue, achieving a net profit of 230 million yuan.

Lin Shi frowned when he saw this: "What the hell is this?" The net profit of 230 million is still ST shares, what is the founder doing? ”

After flipping through the company's announcements in the past October, Lin Shi found that ......

At present, there is even a battle for equity?

Seeing such a big thing, Lin Shi asked the third girl next to him: "Have you paid attention to the stock of ST Tengguang?" ”

Li Xiao frowned: "The stock that has been profitable for seven consecutive years but won't take off its hat?" ”

Lin Shi nodded: "Yes." ”

"I saw it before, and found that the major shareholder was a pit goods, and before the restructuring, he even bought his own shares, and was asked by the relevant departments whether it involved insider trading." Li Xiao said.

Lin Shi was a little puzzled: "But this is a business opportunity, after taking off the hat, it means a huge profit!" ”

Xin Yuting looked at Lin Shi with idiot eyes: "As Sister Li said, ST Tengguang's major shareholder is a pit goods, holding a fragrant dumpling in the industry but not cherishing it, the blood products industry has high barriers and high growth, this industry can't do it with money, and it must be approved by the state, which means that there are not too many competitors, but this major shareholder is unwilling." ”

"The main thing is a matter of trust, on January 27, 2015, ST Tengguang announced the suspension of trading to plan a major asset restructuring, a stop of 300 days, perfect miss the vigorous bull market that year. On October 30, ST Tengguang announced that Tengguang Group, a major shareholder, signed a framework agreement with City A Communications Construction on asset restructuring. Just 5 days ago, on October 25, it also announced that ST Tengguang is planning to raise matching funds for the construction of plasma stations and the construction of the third phase of the blood product production base. ”

"Just said that we want to develop blood products, and in a blink of an eye, we will replace them with the highway assets of City A, ST's Tengguang's pharmaceutical assets have strong profitability, and the company's restructuring is that the major shareholders want to place ST Tengguang's high-quality assets. In this case, the restructuring of ST Tengguang, which had been suspended for ten months, failed and ended hastily. ”

Lin Shi's tone was a little surprised: "What? Suspended for 300 days and missed the 15-year bull market? What is this shareholder thinking? In a bull market, you don't do anything, and the stock price at least doubles, right? What's more, this is a rare blood product stock. ”

Li Xiao looked at Lin Shi, and then reminded: "This stock has been profitable for seven consecutive years but has not taken off the hat, so you don't think that you will take off the hat as soon as you buy it, it is better to be cautious." ”

Lin Shi nodded, he really can't be too hasty when he encounters such a stock, he hasn't taken off his hat for seven consecutive years, who knows if it will be eight consecutive years, ten years, or eleven years?

Although he was a little disappointed with ST Tengguang's major shareholder, Lin Shi decided to read all the public disclosures and news about the stock.

On May 24, 2017, the tender offer suddenly struck, and N City Black Wolf Investment Partnership (Limited Partnership) planned to acquire 26% of the shares of ST Tengguang at a price of 34 yuan, costing up to 2.7 billion yuan. At present, the largest shareholder of ST Tengguang is Tengguang Group, with a shareholding ratio of 23.24%.

Black Wolf Assets and its wholly-owned subsidiaries hold a total of 2.51% of the shares, and after the completion of the offer, Black Wolf and its permanent actors hold a maximum of 29.99% of the shares, and will become the largest shareholder of ST Tengguang and obtain actual control of the company.

It is worth noting that Black Wolf Company stipulates the effective conditions in the offer, if the shares pre-accepted by the offer do not reach 20% of the shares, the tender offer will not take effect, and the pre-accepted shares will not be accepted by the acquirer. In addition, the 2.51% stake already held will also be reduced through centralized bidding, block trading, etc.

And Tengguang Group will not easily be tied down and bury the control of the listed company in vain. On the same day that it received the invitation, ST Tengguang announced that the company was suspended due to major asset restructuring.

Lin Shi looked at the previous restructuring and suspension announcement, and found that ST Tengguang actually wanted to merge and acquire a company bigger than him? And the most coincidental thing is that this company is also a blood product company, the name is Hongde shares, Hongde has a complex equity structure, individuals, institutions, and state-owned shareholders are mixed, and ST Tengguang's controlling shareholder Tengguang Group has bad debts, and its shares have been frozen and pledged for many rounds, and there are almost no other assets to pledge.

Subsequently, ST Tengguang immediately changed a target and changed it to an S market business biotechnology company, which is much smaller than the previous Hongde shares, but the legal person of this company is Ma Tengguang, the actual controller and major shareholder of Tengguang Group.

"Turning around and buying up the stocks in your hands?" Lin Shi smiled bitterly when he saw this, this major shareholder is too capable of tossing.